ABG
ICPT

Ally Bridge Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Ally Bridge Group’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100,000
Closed -$1.4M – 41
2022
Q3 		$1.4M Buy
+100,000
New +$1.61M 0.92% 30

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Ally Bridge Group's ICPT Position: Q4 2022 in Review

Ally Bridge Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 100,000 shares — an estimated $1.4M sold.

Ally Bridge Group first reported a position in ICPT in Q3 2022 and held it in 1 quarter. The position peaked at $1.4M in Q3 2022. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

  • Ally Bridge Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Ally Bridge Group sold 100,000 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $1.4M.
  • Ally Bridge Group first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2022 and held it in 1 quarter.
  • Ally Bridge Group's Intercept Pharmaceuticals, Inc. position peaked at $1.4M in Q3 2022.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on Ally Bridge Group's 13F filing for Q4 2022, filed 14 Feb 2023.